scPharmaceuticals Inc. (SCPH)

NASDAQ: SCPH · IEX Real-Time Price · USD
4.69
0.25 (5.63%)
May 16, 2022 4:30 PM EDT - Market closed
Market Cap128.37M
Revenue (ttm)n/a
Net Income (ttm)-28.03M
Shares Out27.37M
EPS (ttm)-1.03
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume31,978
Open4.61
Previous Close4.44
Day's Range4.61 - 4.72
52-Week Range3.48 - 7.28
Beta0.35
AnalystsBuy
Price Target10.54 (+124.7%)
Earnings DateMay 11, 2022

About SCPH

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-...

IndustryPharmaceuticals
IPO DateNov 17, 2017
CEOJohn Tucker
Employees26
Stock ExchangeNASDAQ
Ticker SymbolSCPH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for SCPH stock is "Buy." The 12-month stock price forecast is 10.54, which is an increase of 124.73% from the latest price.

Price Target
$10.54
(124.73% upside)
Analyst Consensus: Buy
Stock Forecasts

News

scPharmaceuticals Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

FDA assigns PDUFA action date of October 8, 2022

17 hours ago - GlobeNewsWire

scPharmaceuticals Inc. Announces FDA Acceptance of FUROSCIX® New Drug Application

PDUFA action date set for October 8, 2022

17 hours ago - GlobeNewsWire

scPharmaceuticals Inc. Announces Resubmission of FUROSCIX® New Drug Application

Anticipates Q4 2022 commercial launch, if approved Anticipates Q4 2022 commercial launch, if approved

1 month ago - GlobeNewsWire

scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Successfully completed all testing; plan to re-submit FUROSCIX® NDA by April 15, 2022

1 month ago - GlobeNewsWire

scPharmaceuticals to Present at the 42nd Annual Cowen Healthcare Conference

BURLINGTON, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimiz...

3 months ago - GlobeNewsWire

scPharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference

BURLINGTON, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimiz...

3 months ago - GlobeNewsWire

scPharmaceuticals to Participate in Two Upcoming Investor Conferences

BURLINGTON, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimiz...

4 months ago - GlobeNewsWire

scPharmaceuticals Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

All additional testing of devices manufactured on the planned commercial line, as required by the FDA, has been successful to date

6 months ago - GlobeNewsWire

scPharmaceuticals to Present at the Jefferies London Healthcare Conference

BURLINGTON, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimiz...

6 months ago - GlobeNewsWire

scPharmaceuticals Inc. Presents Late-breaking FREEDOM-HF Study Data at the Heart Failure Society of America Annual Sc...

Data show statistically significant and meaningful reduction in both heart failure-related and overall healthcare costs for patients treated with FUROSCIX® versus a historical comparator group

8 months ago - GlobeNewsWire

scPharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

BURLINGTON, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimi...

8 months ago - GlobeNewsWire

scPharmaceuticals Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update

Received minutes from Type C meeting with the FDA confirming alignment on path toward resubmission of FUROSCIX® NDA; no additional clinical data or device modifications required at this time; on track f...

9 months ago - GlobeNewsWire

scPharma's Furoscix Can Potentially Cut Hospital Admission/Readmission Costs For Heart Failure Patients

scPharmaceuticals Inc (NASDAQ: SCPH) announced top-line results from its FREEDOM-HF study evaluating overall and heart failure-related costs of treating congestion in patients with chronic heart failure...

10 months ago - Benzinga

scPharmaceuticals Inc. Announces Positive Top-Line Results from FREEDOM-HF Study

Reduced average 30-day heart failure related costs by $17,753 (p

10 months ago - GlobeNewsWire

scPharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

BURLINGTON, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize...

11 months ago - GlobeNewsWire

scPharmaceuticals Inc. Reports First Quarter 2021 Financial Results and Provides Business Update

FREEDOM clinical study on track for topline results in Q3 2021

1 year ago - GlobeNewsWire

ScPharmaceuticals Sees US Application Submission For Furoscix In Q3

ScPharmaceuticals Inc (NASDAQ: SCPH) announced that after the Type A meeting with the FDA, the agency does not require any modifications to the device, nor it asked the company to conduct additional cli...

1 year ago - Benzinga

scPharmaceuticals Inc. Appoints Renowned Heart Failure Specialist William T. Abraham, M.D.

BURLINGTON, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimiz...

1 year ago - GlobeNewsWire

scPharmaceuticals to Present at the 10th Annual SVB Leerink Global Healthcare Conference

BURLINGTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimiz...

1 year ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of scPharmaceuticals Inc. - SCPH

NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of scPharmaceuticals Inc. ("scPharmaceuticals" or the "Company") (NASDAQ: SCPH). uch investors are ad...

1 year ago - PRNewsWire

scPharmaceuticals (SCPH) Plunges on Complete Response Letter

scPharmaceuticals (SCPH) receives complete response letter from the FDA regarding an NDA for its pipeline candidate, Furoscix, as a potential treatment for congestion due to fluid overload in adult pati...

1 year ago - Zacks Investment Research

FDA Rejects scPharma's Heart Failure Drug For Second Time, Sending Biotech Stock Lower

Scpharmaceuticals Inc (NASDAQ: SCPH) shares were hurtling toward their late March lows Monday after a binary event panned out negatively for the biopharma. What Happened: Burlington, Massachusetts-based...

1 year ago - Benzinga

scPharmaceuticals to Present at the 3rd Annual Evercore ISI Virtual HealthCONx Conference

BURLINGTON, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimiz...

1 year ago - GlobeNewsWire

scPharmaceuticals Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update

Commercial ization preparedness activities continuing ahead of December 30 PDUFA date for FUROS C IX ® (furosemide injection) for subcutaneous administration

1 year ago - GlobeNewsWire

scPharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference

BURLINGTON, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimiz...

1 year ago - GlobeNewsWire